What is the market's earnings forecast for Merit Medical next quarter?

What does Merit Medical do and what are its main business segments?

What were the key takeaways from Merit Medical's earnings call?

What were the key takeaways from Merit Medical’s earnings call?

What is Merit Medical's latest dividend and current dividend yield?

Did Merit Medical beat or miss consensus estimates last quarter?

What is Merit Medical's gross profit margin?

What factors drove the changes in Merit Medical's revenue and profit?

- **Revenue Growth & Margin Expansion**: Q4 2025 revenue up 11% YoY, non-GAAP operating margin 21% (138 bps YoY expansion). Full-year 2025 free cash flow $216 million, exceeding $150M guidance.
- **2026 Guidance**: 6-8% GAAP revenue growth, non-GAAP EPS $4.01-$4.15 (5-8% growth), free cash flow $200M+.
- **Strategic Shifts**: Divestiture of DualCap line to focus on high-margin products; Rhapsody 2026 U.S. revenue guide $7 million reflects cautious rollout.
- **Risks & Challenges**: 2026 faces 140 bps organic growth headwind from DualCap divestiture and $15M annual tariff impact. China growth constrained by VBP in Q1 2026.

**【CEO Summary Section】**
- Reported Q4 2025 revenue of $393.9 million, up 11% YoY (10% constant currency), exceeding high-end guidance. Full-year 2025 revenue grew 11% constant currency, exceeding original 10% guidance.
- Delivered non-GAAP operating margin of 21% in Q4 (up 138 bps YoY) and non-GAAP EPS of $1.04, both beating expectations. Free cash flow reached $74 million (13% YoY growth).
- 2026 guidance: 6-8% GAAP revenue growth (5-7% constant currency), non-GAAP EPS of $4.01-$4.15 (5-8% growth), and free cash flow of at least $200 million.
- Highlighted strategic focus on high-margin therapeutic products and divestiture of DualCap line to free up resources.

**【CFO Financial Commentary】**
- Cardiovascular segment drove 9% revenue growth, with Cardiac Intervention (CI) up 21% (12% organic) and Peripheral Intervention (PI) up 13% (25% growth in radar localization/delivery systems). Endoscopy grew 15%.
- Gross margin improved 103 bps YoY to 54.5%, driven by product mix, pricing, and tariffs (112 bps headwind). Operating expenses rose 10%, but operating income grew 19% to $82.7 million.
- 2026 guidance includes $15 million annual tariff impact and $0.01 EPS dilution from convertible debt. Free cash flow targets $200 million+ despite $90 million CapEx.
- DualCap divestiture (sold for $28M) creates 140 bps headwind to 2026 organic growth but frees up manufacturing capacity.

**【Q&A Highlights】**
- **Gross Margin Drivers**: Raul emphasized ongoing cost control, mix shifts to higher-margin products, and SKU rationalization. 2026 operating margin expected to expand 36-76 bps YoY despite tariffs.
- **Rhapsody Outlook**: 2026 U.S. revenue guide of $7 million reflects cautious expectations for non-hospital adoption. Martha noted Rhapsody's potential as a platform but cautioned against extrapolating early results.
- **China Performance**: 2025 China sales down due to volume-based purchasing (VBP), but 2026 guidance assumes stabilization. Q1 2026 China growth constrained by VBP timing.
- **M&A Strategy**: Martha highlighted focus on therapeutic products and platforms with clinical differentiation. 2026 M&A pipeline includes both tuck-ins and slightly larger deals if strategic fit.

Merit Medical Systems, Inc. (MMSI) Q4 2025 Earnings Call Transcript

- **Record Performance**: Q3 revenue up 13% YoY, non-GAAP EPS of $1.08 beats estimates, 53.6% gross margin (highest in company history). 
- **Strategic Wins**: WRAPSODY CIE adoption exceeds expectations, C2 CryoBalloon acquisition expands endoscopy portfolio. 
- **China Challenges**: Sales down 1% YoY, but VBP impact better than feared; core business volume strong. 
- **Tariff Resilience**: Overcame 90 basis point headwind, with $7.6 million annualized tariff impact. 
- **Free Cash Flow**: $140 million year-to-date, targeting $175 million for 2025 to fund growth and M&A.

**【CEO Summary Section】**
- **Revenue Growth**: Total revenue of $384.2 million, up 13% year-over-year (12.5% on constant currency basis), driven by 7.8% organic growth. Non-GAAP EPS of $1.08 exceeded expectations, with free cash flow of $53 million (38% YoY increase). 
- **Gross Margin Record**: Achieved 53.6% gross margin, a 267 basis point YoY improvement, supported by product mix, pricing, and cost control. 
- **New Product Momentum**: Launched WRAPSODY CIE with strong early adoption in hospitals, and announced C2 CryoBalloon acquisition for gastroenterology. 
- **Strategic Acquisitions**: Completed $22 million acquisition of Pentax's C2 CryoBalloon to expand endoscopy portfolio. 
- **China Market**: Sales decreased 1% YoY, but VBP impact was better than expected, with 2% growth excluding tariffs. 

**【CFO Financial Commentary】**
- **Revenue Breakdown**: Cardiovascular segment grew 29% (excluding acquired products), Endoscopy segment grew 4%. U.S. sales increased 12% (7.6% organic), international sales up 8% (excluding China). 
- **Profitability**: Non-GAAP operating margin of 19.7% (51 basis points YoY improvement), net income of $54.9 million ($0.92 EPS). 
- **Free Cash Flow**: Generated $52.5 million in Q3, with $140 million year-to-date, targeting $175 million for 2025. 
- **Tariff Impact**: Q3 gross margin headwind of 90 basis points from tariffs, with $7.6 million annualized impact. 

**【Q&A Highlights】**
- **WRAPSODY CIE**: Early adoption in hospitals exceeds expectations, with 200+ trained physicians. TPT reimbursement application submitted, expecting Jan 2026 effective date. 
- **Gross Margin Durability**: 53.6% gross margin driven by mix, pricing, and cost control; long-term headroom exists through CGI initiatives. 
- **China Strategy**: Focus on core business growth, with VBP better than expected, but OEM softness due to macro environment. 
- **M&A Cadence**: Small, strategic tuck-ins (e.g., C2 CryoBalloon) to expand endoscopy portfolio, with $140 million+ free cash flow for 2025. 
- **2026 Outlook**: CGI goals remain focus, with no major shifts in capital allocation strategy.

Merit Medical Systems, Inc. (MMSI) Q3 2025 Earnings Call Transcript

- **Record Financials**: Q2 revenue $382.5M (+13% YoY), non-GAAP EPS $1.01 (+10%), highest operating margin (21.2%) in company history.
- **Strategic Moves**: $120M Biolife acquisition for hemostatic devices; Martha Aronson appointed CEO effective Oct 3, 2025.
- **WRAPSODY Delay**: Outpatient reimbursement delayed 6 months; Q2 U.S. sales $2-4M, unchanged long-term growth outlook.
- **Tariff Impact**: High end guidance assumes $7M tariff impact vs. prior $26.3M; low end reflects $26.3M worst-case scenario.
- **China Challenges**: Q2 sales down 6% due to macro environment; APAC growth expected 2-3% YoY.

**【CEO Summary Section】**
- **Revenue Growth**: Q2 2025 revenue of $382.5M (+13% YoY, +12.5% constant currency), exceeding high-end guidance. Organic constant currency growth of 6.7% vs. 6% target.
- **Profitability**: Non-GAAP operating margin 21.2% (+109bps YoY), highest in company history. Non-GAAP EPS up 10% to $1.01, free cash flow $70M (+20% YoY).
- **Strategic Acquisitions**: $120M Biolife acquisition for hemostatic devices (StatSeal/WoundSeal), targeting $350M global market. Martha Aronson appointed President & CEO effective Oct 3, 2025.
- **WRAPSODY Update**: U.S. commercial strategy progressing, but outpatient reimbursement delayed 6 months due to CMS process. Q2 U.S. sales $2-4M, unchanged long-term growth outlook.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: Cardiovascular (+10%), Endoscopy (+81%). Excluding acquisitions, organic growth 6.8% (Cardio) and 1% (Endo). U.S. sales +17% constant currency, intl +7% YoY (APAC strong, EMEA flat, China -6%).
- **Margins**: Gross margin 53.2% (+167bps YoY), driven by lower tariffs, mix, and pricing. Operating expenses +15% (SG&A +13%, R&D +24%).
- **Guidance Update**: 2025 GAAP revenue +10-11%, non-GAAP EPS $3.52-3.72 (+$0.24 low end, +$0.31 high end). Free cash flow ≥$150M. Q3 non-GAAP EPS $0.76-0.85.
- **Tariff Impact**: High end assumes $7M tariff impact vs. prior $26.3M. Low end reflects $26.3M impact, reflecting uncertainty.

**【Q&A Key Highlights】**
- **WRAPSODY Reimbursement**: CMS denied APC assignment for outpatient setting; resubmitted TPT application by Sep 1, 2025. Delayed effective date to Jan 1, 2026. Company maintains premium pricing strategy.
- **China Sales**: Q2 down 6% due to macro environment, not VBP. APAC growth expected 2-3% YoY, China low single digits.
- **Tariffs**: Q2 impact $2M, but high uncertainty. Company mitigating via shipment redirects and product transfers.
- **Biolife Integration**: Direct distribution replacing 4 U.S. distributors. International growth potential via Merit's global footprint.
- **CEO Transition**: Fred remains Chairman; Martha Aronson brings industry expertise to lead next phase of growth.


Merit Medical Systems, Inc. (MMSI) Q2 2025 Earnings Call Transcript

- **Q1 Growth & Margin Wins**: 10.9% constant currency revenue growth, 19.3% operating margin, and $1.08 EPS beat reflect strong execution and CGI initiatives.
- **Tariff Headwinds**: $26.3M annualized tariff impact reduces 2025 EPS by $0.34, but 45% offset potential via CGI and operational shifts.
- **U.S. Strength & China Challenges**: 14% U.S. growth vs. 10% China decline, with China tariffs driving 94% of tariff costs.
- **Endoscopy Surge**: 64% growth from acquisitions, positioning for 34-37% 2025 segment expansion.
- **OEM Momentum**: 21% Q1 growth highlights Medtronic deal success and CGI pricing discipline.

**【CEO Summary Section】**
- Total revenue for Q1 2025 was $355.4 million, up 9.8% YoY (10.9% on a constant currency basis), driven by 6% organic growth in the U.S. and strong execution across all segments.
- Non-GAAP operating margin improved 229 basis points YoY to 19.3%, with non-GAAP EPS up 15% to $1.08, exceeding high-end guidance.
- 2025 revenue guidance reaffirmed at 8-10% YoY growth, with updated non-GAAP EPS range of $3.29-$3.42 due to $26.3 million tariff-related cost headwinds.

**【CFO Financial Commentary】**
- Cardiovascular segment revenue grew 9%, with Cardiac Intervention products up 12% (2% organic) and Peripheral Intervention up 6.8%.
- Endoscopy segment revenue surged 64% on acquisitions, while U.S. sales increased 14% (13% in Q2 guidance) and international sales grew 1.9% on a constant currency basis.
- Gross margin expanded 251 basis points to 53.4%, driven by product mix, pricing, and cost efficiencies.
- Free cash flow of $19.5 million in Q1, with 2025 guidance for at least $150 million despite $90-100 million in CapEx for a new distribution center.

**【Tariff Impact & Mitigation】**
- $26.3 million annualized tariff headwind (94% from China) reduces 2025 non-GAAP EPS by ~$0.34, offsetting $0.05 from lower convertible debt dilution.
- Mitigation strategies include CGI initiatives (45% potential offset), inventory redirection, and operational efficiency improvements.

**【Key Market Insights】**
- U.S. demand strong with 14% growth, while China faced 10% revenue decline due to macro factors, though VBP impact was in line with expectations.
- OEM business grew 21%, driven by Medtronic's Arcadia deal and CGI-driven pricing discipline.
- WRAPSODY CIE U.S. revenue guidance remains $7-9 million, with CMS NTAP approval proposed for FY26 at $3,770 add-on payment.

Merit Medical Systems (MMSI)-24 Apr 25-2025 Q1 Earnings call transcript

- **Q4 Revenue Beat**: 10% constant currency growth vs. 6-9% guidance, driven by strong U.S. demand and acquired products.
- **Margin Expansion**: 19.6% operating margin (up 305 bps YoY) and record 51.7% gross margin in 2024.
- **2025 Guidance**: 8-10% revenue growth, 4-7% EPS growth, and $150M+ free cash flow despite $0.11 EPS dilution.
- **Key Risks**: Tariff uncertainty, EGS/Cook integration challenges, and China volume-based procurement headwinds.
- **Growth Drivers**: WRAPSODY CIE launch, OEM strength, and 2026 CGI targets of 20%+ operating margin and $400M+ FCF.

**【CEO Summary Section】**
- Fourth quarter revenue reached $355.2 million, up 9% YoY (GAAP) and 10% YoY (constant currency), exceeding the high end of the 6-9% guidance range.
- Non-GAAP operating margin expanded to 19.6%, up 305 basis points YoY, driven by stronger-than-expected revenue and cost control.
- Full year 2024 highlights include 8% constant currency revenue growth, record 51.7% non-GAAP gross margin, and $185 million free cash flow (up 67% YoY).
- 2025 guidance: 8-10% GAAP revenue growth, $3.58-$3.70 non-GAAP EPS (4-7% growth), and at least $150 million free cash flow.

**【CFO Financial Commentary】**
- Q4 gross margin improved to 53.5% (up 304 bps YoY) due to favorable product mix, pricing, and cost reductions.
- Operating expenses increased 9% YoY, with R&D up 26% due to investments in growth initiatives.
- Q4 non-GAAP EPS of $0.93 exceeded expectations, driven by 26% YoY growth in earnings.
- 2025 financial targets include 19.4-19.7% non-GAAP operating margin and $400 million+ free cash flow by 2026.

**【Q&A Key Highlights】**
- **EPS Guidance**: 2025 EPS growth constrained by $5 million incremental interest expense and $0.11 dilution from convertible debt, offsetting 9-12% core growth.
- **Endoscopy Segment**: 88% YoY growth in Q4, but 2025 guidance reflects cautious integration of EGS and Cook Medical acquisitions.
- **Tariff Risk**: 2025 guidance assumes no new tariffs, but company monitors potential impacts on Mexico manufacturing.
- **WRAPSODY CIE**: U.S. sales expected $7-9 million in 2025, with international adoption supported by positive clinical data.
- **OEM Growth**: 22% Q4 growth driven by U.S. demand, with 2025 organic growth expected in low single digits.


Actual											0.38	0.31	0.42	0.54	0.52	0.62	0.52	0.71	0.53	0.73	0.64	0.79	0.64	0.81	0.75	0.81	0.77	0.92	0.86	0.93	0.86	1.01	0.92	1.04
Forecast											0.26	0.065	0.1975	0.4338	0.3575	0.4475	0.4363	0.5057	0.4657	0.5771	0.5286	0.6714	0.5457	0.7521	0.6471	0.7663	0.7144	0.874	0.798	0.8289	0.749	0.8507	0.8278	0.9543
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+46.15%	+376.92%	+112.66%	+24.48%	+45.45%	+38.55%	+19.18%	+40.40%	+13.81%	+26.49%	+21.07%	+17.66%	+17.28%	+7.70%	+15.90%	+5.70%	+7.78%	+5.26%	+7.77%	+12.20%	+14.82%	+18.73%	+11.14%	+8.98%

MMSI

MMSI fundamentals

MMSI Q4 2025 Earnings

Earnings Call

You can ask Aime

MMSI

MMSI fundamentals

MMSI Q4 2025 Earnings

Earnings Call

MMSI Earnings Call Summary for Q4/20255:30 PM on Feb 24, 2026

MMSI Earnings Call Summary for Q3/20255:00 PM on Oct 30, 2025

MMSI Earnings Call Summary for Q2/20255:00 PM on Jul 30, 2025

MMSI Earnings Call Summary for Q1/20255:00 PM on Apr 24, 2025

MMSI Earnings Call Summary for Q4/20245:00 PM on Feb 25, 2025

You can ask Aime